Bluejay Therapeutics

Hepatitis virus
#Bluejay Therapeutics #Clinical trial #hepatitis

Hepatitis D drug achieves 100% virologic response 

Biopharmaceutical company Bluejay Therapeutics’ hepatitis drug candidate has achieved a 100% virologic response at week 48 of clinical trials.  Brelovitug, an investigational, fully human, high-affinity monoclonal antibody (mAb), targets hepatitis B virus surface antigen (anti-HBsAg) in chronic hepatitis D (CHD). The company announced brelovitug achieved 100%… Read More

#News

Monoclonal antibody
#Bluejay Therapeutics #Clinical trial #hepatitis #Monoclonal antibodies #Viral hepatitis

Trial investigates monoclonal antibody for chronic hepatitis D

Bluejay Therapeutics’ AZURE-1 global pivotal clinical trial evaluating brelovitug (BJT-778) for the treatment of chronic hepatitis D (CHD) has dosed its first patient.   Brelovitug is an investigational fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the hepatitis D virus… Read More

#News